600671.SH
天目药业
SSE · Healthcare · Drug Manufacturers - General · CN
CNY 19.84
−3.27%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 203.8M | 211.8M | 217.3M | 121.8M | 108.9M |
| Cost of Revenue | 99.8M | 110.6M | 114.3M | 95.2M | 83.9M |
| Gross Profit | 104.0M | 101.1M | 103.0M | 26.5M | 25.0M |
| Operating Expenses | |||||
| R&D Expense | — | — | 1.2M | 482.2K | 1.6M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 68.2M | 68.4M | 58.0M | 45.2M | 45.7M |
| Selling & Marketing Expense | 14.6M | 13.5M | 8.2M | 2.5M | 6.1M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 92.8M | 91.5M | 74.5M | 56.3M | 61.7M |
| Cost and Expenses | 192.6M | 202.1M | 188.9M | 151.5M | 145.6M |
| Operating Income (EBIT) | 9.7M | 8.4M | 25.1M | (37.6M) | (69.9M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 11.6M | 10.2M | 29.1M | (36.3M) | (72.4M) |
| Income Tax Expense | 4.2M | 3.0M | 7.2M | 3.0M | 757.4K |
| Bottom Line | |||||
| Net Income | 16.3M | 17.6M | 15.2M | (38.3M) | (67.5M) |
| Earnings from Cont. Ops | 7.4M | 7.2M | 21.9M | (39.0M) | (66.6M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 16.3M | 17.6M | 15.2M | (38.3M) | (67.5M) |
| Per Share | |||||
| Basic EPS | CN¥0.13 | CN¥0.14 | CN¥0.13 | (CN¥0.31) | (CN¥0.55) |
| Diluted EPS | CN¥0.13 | CN¥0.14 | CN¥0.13 | (CN¥0.31) | (CN¥0.55) |
| Revenue Per Share | CN¥1.67 | CN¥1.74 | CN¥1.78 | CN¥1.00 | CN¥0.89 |
| Shares | |||||
| Basic Shares Outstanding | 121.9M | 121.8M | 121.8M | 121.8M | 121.8M |
| Diluted Shares Outstanding | 121.9M | 121.8M | 121.8M | 121.8M | 121.8M |
| Profitability Metrics | |||||
| EBITDA | — | 35.4M | 40.4M | (25.2M) | (52.6M) |
| D&A | — | 27.0M | 15.3M | 12.4M | 17.3M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026